Drug Approval | November 16, 2023
Imfinzi plus chemotherapy approved in China as for metastatic biliary tract cancer
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
The companies will work with investigators to share the results with the scientific community
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU
The company is already marketing the 4 mg and 10 mg strengths
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
Based on a subgroup analysis by PD-L1 expression from KEYNOTE-811, Merck is working with the US FDA to update the current indication for KEYTRUDA in HER2-positive gastric or GEJ adenocarcinoma
Ministry of Health, Labour and Welfare to evaluate zolbetuximab as treatment option for patients with advanced gastric and gastroesophageal cancers
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
Subscribe To Our Newsletter & Stay Updated
